ArticleInsights into imaging2026
Evaluating the biopsy-negative prostate lesions based on sequential biparametric prostate magnetic resonance imaging: Can PRECISE be used to guide repeat biopsy?
Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveIndications for repeat biopsy after an initial negative prostate biopsy remain poorly defined. Therefore, this study aimed to investigate the effectiveness of the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) scoring system as a guide for repeat biopsy. MATERIALS AND
methodsWe retrospectively reviewed patients who underwent repeat prostate biopsy and had bpMRI performed before both biopsies between 2013 and 2024. The association of clinically significant prostate cancer (csPCa) detection with initial Prostate Imaging Reporting and Data System (PI-RADS) and PRECISE scores was analyzed. The predictive effects of prostate-specific antigen density before repeat biopsy (re-PSAD) and PSA velocity (PSAV) on csPCa were assessed in patients progressing to or maintaining re-PI-RADS 3.
results104 individuals were included with a median follow-up period of 28.58 months and a PSAV of 0.90 ng/mL/year (interquartile range (IQR), -0.17 to 2.57 ng/mL/year). The csPCa detection rate at repeat biopsy was 24.0%. 42 participants (40.4%) had PRECISE scores of 4-5, 43 (41.3%) had scores of 3, and 19 (18.3%) had scores of 1-2. A higher PRECISE score corresponds to a higher csPCa detection rate, with csPCa diagnosed in 52.4% of patients with PRECISE scores of 4-5. In subgroup analyses, re-PSAD and PSAV avoided 65.4% and 53.8% of repeat biopsies, respectively, and would have caused 5.9% and 0.00% of missed csPCa.
conclusionsPRECISE may be useful for guiding repeat biopsy decisions and may provide incremental value for predicting csPCa when interpreted together with PI-RADS. Additionally, PSAD and PSAV can assist in screening for repeat biopsy. KEY POINTS: Question Indications for repeat prostate biopsy after an initial negative result remain poorly defined. Can sequential MRI PRECISE scoring help inform repeat biopsy decisions? Findings In our retrospective cohort, PRECISE 1-2 yielded no clinically significant cancer, while PRECISE 4-5 showed a 52.4% detection rate. PSA parameters aided equivocal cases. Critical relevance statement This study evaluates sequential MRI PRECISE scoring, suggesting its potential to help reduce unnecessary repeat biopsies for regressing lesions while identifying high-risk progressing abnormalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.